Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

(Photo: http://photos.prnewswire.com/prn
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)... 20, 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Surgeons Annual Meeting that they have joined forces ... The collaboration is the first of its kind ... patient outcomes. NICO,s BrainPath® interventional access technology and ...
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... the first and only 10% liquid intravenous immunoglobulin ... well tolerated in patients with several primary and ... the XIVth Meeting of the European Society for ... offers significant protection against infection. In ...
... Oct. 6 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... market conditions, to offer 4,500,000 shares of its common stock ... sole bookrunner.   The Company expects to use ... general corporate purposes.  Closing of the offering is expected to ...
Cached Medicine Technology:Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock 2Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock 3
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... Arlington Innovation Center: Health Research (AiC: Health Research), of ... $1.5 million cooperative research and development agreement from the ... agreement also includes an option for approximately $3 million ... The Virginia Tech project team is led by ...
... QUE. -- Women throughout the world will benefit from ... that aims to change the way in which ovarian ... Canadian Partnership Against Cancer are providing a total of ... Pan-Canadian Program called COEUR. The program will identify new ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Changes in the ... pancreatic cancer, preliminary research reveals. The small study suggests ... deadly disease simply by analyzing a patient,s saliva, as the ... a higher risk. The observation, however, raises the question: ...
... helicopter, an expensive choice that may not impact patient outcome ... time is of the essence, helicopter transport is generally assumed ... ambulance, but a paper published today in the online journal ... the actual times to treatment for patients transported by helicopter ...
... News) -- Vitamin D plays a critical role in the ... a potentially fatal lung disease, according to a new study. ... D, which is a natural hormone, is linked to human ... autoimmune diseases. In conducting the study, the ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
Cached Medicine News:Health News:US Army awards $1.5 million for sleep research 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 3Health News:Oral Bacteria Might Signal Early Pancreatic Cancer 2Health News:Oral Bacteria Might Signal Early Pancreatic Cancer 3Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Research Sheds Light on Vitamin D's Role in Immunity 2Health News:Research Sheds Light on Vitamin D's Role in Immunity 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2
Angulated, blunt tips....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
... All Bovie LLETZ Loop ... wire for superior shape and ... They use a standard 3/32" ... loops are packaged in a ...
7 1/2" Handswitch Monopolar Forceps, Ins., Curved, Serrated...
Medicine Products: